| Name | Title | Contact Details |
|---|
22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. 22nd Century owns or is the exclusive licensee of 116 issued patents in 78 countries plus an additional 42 pending patent applications. Goodrich Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century. Goodrich Tobacco is focused on commercial tobacco products and potentially less harmful cigarettes. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.
Founded in 2006, InGeneron is a privately held company, developing its own products for multiple markets and expanding its reach through licensing agreements. The company was formed to innovate cell-based technologies for healthcare and life science research. Headquartered in Houston, Texas,
The combined characteristics of a modern machine (with a touch of humanity) and mythical creature symbolizes Lykan Bioscience™ as a company. The team at Lykan Bioscience operates with a highly advanced way of thinking. We offer our clients speed, agility, and control while accelerating their cell and gene therapy products from clinical through to commercial manufacturing. As part of your team, our Manufacturing Services Organization™ (MSO) will transform what is traditionally offered in the CGT industry, as we guide you through your manufacturing journey. Our mission is to partner with our clients, to maximize patient accessibility and expedite time to market for cell-based therapies.
ChemImage is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marsh is a global leader in insurance broking and risk management. Marsh helps clients succeed by defining, designing, and delivering innovative industry-specific solutions that help them effectively manage risk. Marsh’s approximately 26,000 colleagues work together to serve clients in more than 130 countries. Marsh is a wholly owned subsidiary of Marsh & McLennan Companies (NYSE:MMC), a global professional services firm offering clients advice and solutions in the areas of risk, strategy, and human capital. With 55,000 employees worldwide and annual revenue exceeding $12 billion, Marsh & McLennan Companies is also the parent company of Guy Carpenter, a global leader in providing risk and reinsurance intermediary services; Mercer, a global leader in talent, health, retirement, and investment consulting; and Oliver Wyman, a global leader in management consulting.